Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLOD2 | O00469 | 3/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | PLOD3 | O60568 | 2/20 | 0.53 |
| ▸ | PLOD1 | Q02809 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | MPO | P05164 | 1/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.43 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31466251 | 0.80 | PLOD2 (0.58) | PLOD2CYP1A2CYP2C19ALDH1A1PLOD3 | |
| SCHEMBL1919299 | 0.78 | PLOD2 (0.60) | PLOD2CYP1A2CYP2C19ALDH1A1PLOD3 | |
| SCHEMBL10948430 | 0.77 | PLOD2 (0.83) | PLOD2CYP1A2CYP2C19ALDH1A1PLOD3 | |
| SCHEMBL31465822 | 0.77 | PLOD2 (0.58) | PLOD2CYP1A2CYP2C19ALDH1A1PLOD3 | |
| SCHEMBL31407204 | 0.76 | L3MBTL1 (0.56) | PLOD2CYP1A2CYP2C19ALDH1A1PLOD3 | |
| SCHEMBL1062957 | 0.75 | PLOD2 (0.56) | PLOD2CYP1A2CYP2C19ALDH1A1PLOD3 | |
| SCHEMBL27908332 | 0.74 | PLOD2 (0.55) | PLOD2CYP1A2CYP2C19ALDH1A1PLOD3 | |
| SCHEMBL3108729 | 0.74 | PLOD2 (0.64) | PLOD2CYP1A2CYP2C19ALDH1A1PLOD3 | |
| SCHEMBL2587127 | 0.72 | ALDH1A1 (0.53) | PLOD2CYP1A2CYP2C19ALDH1A1PLOD3 | |
| SCHEMBL15635368 | 0.72 | GRM4 (0.50) | ALDH1A1HPGDL3MBTL1KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9260395-B2 | Inhibitors of viral replication, their process of preparation and their therapeutical uses | LABORATOIRE BIODIM (FR) | 2016-02-16 | — | — | US | disclosed |
| US-9260395-B2 | Inhibitors of viral replication, their process of preparation and their therapeutical uses | LABORATOIRE BIODIM (FR) | 2016-02-16 | — | — | US | disclosed |
| US-9260395-B2 | Inhibitors of viral replication, their process of preparation and their therapeutical uses | LABORATOIRE BIODIM (FR) | 2016-02-16 | — | — | US | disclosed |
| US-20150274673-A1 | Inhibitors of Viral Replication, Their Process of Preparation and Their Therapeutical Uses | HIVIH (FR) | 2015-10-01 | — | — | US | disclosed |
| US-20150274673-A1 | Inhibitors of Viral Replication, Their Process of Preparation and Their Therapeutical Uses | HIVIH (FR) | 2015-10-01 | — | — | US | disclosed |
| US-20150274673-A1 | Inhibitors of Viral Replication, Their Process of Preparation and Their Therapeutical Uses | HIVIH (FR) | 2015-10-01 | — | — | US | disclosed |
| EP-2903969-A1 | INHIBITORS OF VIRAL REPLICATION, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES | LABORATOIRE BIODIM (FR) | 2015-08-12 | — | — | EP | disclosed |
| WO-2014053665-A1 | INHIBITORS OF VIRAL REPLICATION, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES | LABORATOIRE BIODIM (FR) | 2014-04-10 | — | — | WO | disclosed |
| US-7479501-B2 | Heteroaryl-cyclic acetals | AVENTIS PHARMA LIMITED (GB) | 2009-01-20 | — | — | US | disclosed |
| US-20050090501-A1 | Heteroaryl-cyclic acetals | AVENTIS PHARMA LIMITED (GB) | 2005-04-28 | — | — | US | disclosed |
| EP-1140916-B1 | HETEROARYL-CYCLIC ACETALS | AVENTIS PHARMA LTD (GB) | 2002-11-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150274673-A1 | Inhibitors of Viral Replication, Their Process of Preparation and Their Therapeutical Uses | RPL35, EIF2AK2, POLRMT | PLOD2 4447/4885CYP1A2 2632/4885CYP2C19 2416/4885 |
| US-20050090501-A1 | Heteroaryl-cyclic acetals | TNF, TNFRSF1A, CD40 | PLOD2 3250/4885CYP1A2 63/4885CYP2C19 128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.